{
    "Trade/Device Name(s)": [
        "Aptima HCV Quant Dx Assay"
    ],
    "Submitter Information": "Hologic, Inc.",
    "510(k) Number": "K233352",
    "Predicate Device Reference 510(k) Number(s)": [
        "P160023"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MZP"
    ],
    "Summary Letter Date": "June 28, 2024",
    "Summary Letter Received Date": "July 1, 2024",
    "Submission Date": "July 18, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.3170"
    ],
    "Regulation Name(s)": [
        "Nucleic Acid-Based Hepatitis C Virus Ribonucleic Acid Tests"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "Hepatitis C virus (HCV) RNA"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "ACD solution tube",
        "Plasma Preparation Tube (PPT)",
        "Serum tube",
        "Serum Separator Tube (SST)"
    ],
    "Instrument(s)/Platform(s)": [
        "Panther system"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time Transcription-Mediated Amplification (TMA)",
        "Nucleic acid amplification",
        "Fluorescent probe detection"
    ],
    "Methodologies": [
        "Transcription-mediated amplification",
        "Automated nucleic acid extraction",
        "Real-time quantitation"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Software",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for Aptima HCV Quant Dx Assay using real-time TMA on the Panther system for detection and quantitation of HCV RNA in serum and plasma",
    "Indications for Use Summary": "Aid in diagnosis of active HCV infection and management of HCV-infected patients receiving antiviral therapy by quantitating HCV RNA in serum and plasma; not approved for blood or blood product screening",
    "fda_folder": "Microbiology"
}